Minireviews
Copyright ©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Dec 10, 2014; 5(5): 1028-1035
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.1028
Table 1 Selected grade 3/4 adverse events (%) with FOLFIRI/ziv-aflibercept in VELOUR study
Adverse eventGrade 3 %Grade 4 %
Fatigue11.90.7
Asthenia4.90.2
Proteinuria7.50.3
Urinary tract infections0.80.0
Neutropenia23.113.6